Skip to main content
Quest Diagnostics

Cardiometabolic Disease Assessment (CMDA) Panel

Cardiometabolic disease is complex–your assessment doesn't have to be

With just 1 panel and enhanced report, Quest Diagnostics makes it easier to identify and monitor cardiometabolic disease

Nearly half of Americans have a chronic disease; more than half of older adults have 3 or more chronic conditions.1 Medical societies such as the American Heart Association®, American Association of Clinical Endocrinology®, and the National Kidney Foundation® recognize the interrelated impacts of cardiometabolic conditions as well as the importance of prevention, early identification, and management of these conditions.

Cardiometabolic Disease Assessment (CMDA) Panel

Chronic condition    Test(s) included in CMDA Panel  
Glycemic control Hemoglobin A1c (HbA1c), Insulin Resistance Panel with Score
Cardiovascular disease Lipid Panel, Apolipoprotein B (ApoB)
Endocrine disorders Thyroid Stimulating Hormone (TSH)
Chronic kidney disease Kidney Profile
Nonalcoholic fatty liver disease (NAFLD) Comprehensive Metabolic Panel (CMP) with FIB-4 Index

Panel components may be ordered separately

The Cardiometabolic Disease Assessment (CMDA) Panel with enhanced report provides a comprehensive and streamlined overview of cardiometabolic disease

Seven guideline-recommended and specialty tests combined in a single panel with 1 test code and a consolidated enhanced report deliver detailed results, empowering treatment strategies to help prevent, reverse, or slow the progression of multiple cardiometabolic diseases.

See test information

Who should be tested?

Cardiometabolic assessment may be considered for patients annually. Testing is suitable for individuals who are affected by

  • Obesity (BMI > 25)
  • Hypertension
  • History of gestational diabetes, preeclampsia, or PCOS
  • Erectile dysfunction
  • History of cardiovascular disease
  • Metabolic and endocrine disorders that contribute to cardiometabolic risk, including
    • HbA1c ≥ 5.5%
    • Hyper-/hypothyroidism
    • Primary aldosteronism

Additional factors for consideration include age (> 45 male, > 50 female), family history, and sedentary lifestyle. End organ disease assessment can be followed by disease-specific marker investigation.

Insights across the continuum, from early identification to disease management

Identify and monitor the intersection of cardiometabolic disease presence and downstream effects across organ systems

Integrate the latest guideline and clinical recommendations in practice

Streamline cardiometabolic disease assessment, interpretation, and follow-up

Learn more about the CMDA Panel

Download brochure

Actionable results with our enhanced report

A consolidated enhanced report makes it easier to identify cardiometabolic disease presence, assess disease progression, and follow up with patient progress. Color-coded visual representation of results alongside historical results from prior visits help you track your patient's health journey over time.
Explore the enhanced report
CMDA Panel enhanced report thumbnail

References

1. Raghupathi W, Raghupathi V. An empirical study of chronic diseases in the United States: a visual analytics approach. Int J Environ Res Public Health. 2018;15(3):431. doi:10.3390/ijerph15030431

Bridge the gap between chronic cardiometabolic conditions

Ready to learn more about Quest's streamlined, comprehensive solution for cardiometabolic disease assessment?

Contact us

Get up to speed on the CMDA Panel in just 7 minutes

Listen to our Healthier World podcast episode, Instant Insights: Streamlining cardiometabolic disease assessment

Listen now

Read more about testing solutions for chronic cardiometabolic and endocrine conditions

Worth a listen

Healthier World with Quest Diagnostics aims to prompt action from insight as we keep you up to date on current clinical and diagnostic topics in cardiovascular, metabolic, endocrine, and wellness medicine

 

Audio Podcast
The Cardiometabolic Approach: A Solution to Modern Disease Risk Assessment
Pathology & Laboratory Medicine
Audio Podcast
The Insulin Resistance Revolution: The Key to Preventing Chronic Conditions
Health & Wellness
Audio Podcast
Instant Insights: Apolipoprotein B
Pathology & Laboratory Medicine
Audio Podcast
Instant Insight: Kidney Profile and Cystatin C
Pathology & Laboratory Medicine
Audio Podcast
Instant insights: Rethinking Primary Aldosteronism Diagnosis
Find all episodes

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.